HSDT$3.2058
Chart
Performance
Key Stats
AI HSDT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralHelius Medical Technologies (HSDT) presents a mixed investment profile. Fundamentally, the company is in a challenging financial position with significant net losses and negative free cash flow. While there are no immediate positive thematic drivers apparent from the provided data, technical indicators show some short-term oversold conditions that could lead to a temporary rebound. Investors should exercise extreme caution and consider this a highly speculative investment.
Thematic
The provided data does not indicate any strong thematic tailwinds for Helius Medical Technologies. The company operates in the neurotechnology space with a focus on neurological disease treatment, but specific market trends or growth drivers are not detailed. The lack of clear positive thematic alignment makes it less attractive from this perspective.
Fundamental
Helius Medical Technologies faces significant fundamental challenges. It exhibits persistent negative net income, substantial operating losses, and negative free cash flow. While it has some cash and equivalents, its debt level is low but the coverage is extremely weak due to poor cash flow generation. The company's valuation metrics are highly distorted due to its small market capitalization and significant losses.
Technical
Helius Medical Technologies (HSDT) shows a strongly bearish technical picture. The stock has experienced a catastrophic price decline over multiple timeframes. While short-term oscillators suggest oversold conditions, the overwhelming trend and momentum indicators are negative. Support levels are being significantly breached, indicating further downside potential.
| Factor | Score |
|---|---|
| Neurotechnology Advancement | 30 |
| Medical Device Innovation | 20 |
| Healthcare Sector Trends | 15 |
| Regulatory Landscape | 10 |
| Market Expansion Potential | 25 |
| Factor | Score |
|---|---|
| Valuation | 5 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 10 |
| Cash Flow | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 10 |
| Momentum | 50 |
| Volume Confirmation | 20 |
| Support & Resistance | 15 |
| Short-Term Oscillators | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improving Cash Position
The company's cash and cash equivalents have increased significantly, from $5.18M in Q4 2023 to $10.88M in Q4 2024, indicating improved liquidity.
Potential for Revenue Turnaround
While recent quarterly revenue has been low, the projected revenue for Q2 2025 is an average of $75,000, suggesting a potential stabilization or slight increase after recent declines.
Bearish Points (8)
Significant Share Price Decline
The stock has experienced severe performance degradation, with a 6-month decline of -98.26% and a 1-year decline of -98.49%, indicating substantial investor losses and negative sentiment.
Extremely High Price-to-Sales Ratio
The TTM Price-to-Sales (PS) ratio is 22.6, and the FY2024 PS ratio is an exceptionally high 676.4, indicating the stock is trading at a very high multiple relative to its revenue, suggesting potential overvaluation or business model issues.
Calendar
January 2021
4
Next Dividend Date
August 2025
11
Next Earnings Date
H: $
A: $
L: $
H: 75.00K
A: 75.00K
L: 75.00K
Profile
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in medical technology, including a vast neurovascular and neurostimulation portfolio, directly competing or offering alternative/complementary therapies in neuromodulation for neurological disorders, similar to HSDT's focus.
Weight: 90
Major developer of medical devices, with a significant presence in neuromodulation for pain and movement disorders, a direct peer to HSDT in the neurostimulation space.
Weight: 88
Diversified healthcare company with a strong medical device segment, including neurostimulation products for chronic pain and movement disorders, making it a key competitor or analog to HSDT.
Weight: 85
Specializes in neuromodulation therapies, particularly spinal cord stimulation for chronic pain, sharing similar underlying technological principles with HSDT's approach to neurological intervention.